telisotuzumab

Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.

Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.

Telisotuzumab Adizutecan (ABBV-400) is an antibody-drug conjugate (ADC) targeting c-Met. It consists of the humanized anti-c-Met antibody Telisotuzumab, a stable cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), and a topoisomerase 1 inhibitor (7-MAD-MDCPT). The drug-linker conjugate of the ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT. Telisotuzumab Adizutecan exhibits significant antitumor activity against advanced solid tumors such as colorectal, gastric, and non-small cell lung cancers.